Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High?

The consensus price target hints at a 60.6% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Dec 12, 2025

The Best Cheap Stocks Under $10 to Buy in December and 2026

Today, we explore how investors can find the best-in-class cheap stocks trading for under $10 a share to buy now.

Zacks Investment Research • Dec 9, 2025

Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research • Dec 5, 2025

Can Galafold Continue to Drive Amicus' Top Line in 2026?

FOLD leans on rising Galafold sales on the back of strong commercial execution as momentum builds into 2026.

Zacks Investment Research • Dec 5, 2025

Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 4, 2025

Wall Street Analysts Think Amicus Therapeutics (FOLD) Could Surge 58.46%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 58.5% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Nov 26, 2025

Amicus Therapeutics: Moving Towards Consistent Profitability

Amicus Therapeutics (FOLD) is progressing toward profitability, driven by strong Q3 results and expanding global approvals for its rare disease therapies. FOLD's revenue grew 19.5% year-over-year, with Galafold and Pombiliti + Opfolda showing robust sales growth and management reaffirming FY2025 guidance. Amicus recently added DMX-200 to pipeline, licensing it from Dimerix, and targets FSGS, a rare kidney disease, and could add significant future growth potential for FOLD.

Seeking Alpha • Nov 11, 2025

Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript

Amicus Therapeutics, Inc. ( FOLD ) UBS Global Healthcare Conference 2025 November 10, 2025 2:45 PM EST Company Participants Jeffrey Castelli - Chief Development Officer Presentation Unknown Analyst Great. Okay. Well, thanks, everyone, for joining us.

Seeking Alpha • Nov 10, 2025

Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade

The consensus price target hints at a 76.3% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 10, 2025

Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns

EVER, FOLD, LRCX and CBOE make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.

Zacks Investment Research • Nov 7, 2025